Pancreas transplantation. results during the R406 besylate next era of immunosuppression, that may move from common protocols to patient-specific optimization. 0.05).9 However, in these early studies using ATG preparations for induction in combination with azathioprine with or without steroids, there were mixed results; several studies failed to demonstrate significant reductions in rejection rates or improved graft survival.10C13 In the 1980s, cytolytic antibody induction using either polyclonal preparations (rATG and horse ATG [hATG]) or monoclonal therapy (muromonab-CD3) demonstrated reductions in acute rejection, with some studies demonstrating improved 1-yr graft survival as well.14,15 As potent maintenance immunosuppression regimens took hold in R406 besylate transplantation, the widespread use of induction therapy diminished in the 1980s through the mid-1990s. This is true not only for kidney transplant recipients, but also within liver, heart, and lung transplantations.16 In the mid to late 1990s, the use of antibody induction therapy in kidney transplantation started to reemerge like a common modality used to prevent rejection and improve outcomes.7,12,15C17 This was driven by several innovative therapies gaining US Food and Drug Administration (FDA) authorization, particularly anti-CD25 antibodies (basiliximab and daclizumab), which were tested in large-scale studies demonstrating security and effectiveness. The anti-CD25 antibody therapies displayed a new class of providers that, for the first time, were not cytolytic, but rather blunted the activation and propagation of T-helper cells. These agents were considered less potent than cytolytic therapies (rATG, hATG, and muromonab-CD3), but also safer and better tolerated with a lower risk of infections, particularly cytomegalovirus (CMV).13,16,18,19 There were several pivotal trials demonstrating encouraging outcomes. The study by Kahan and colleagues20 (Table 1), which compared basiliximab to placebo with all receiving cyclosporine and prednisone maintenance immunosuppression, reduced rejection rates from 49% in the control arm to 35% in the treatment arm. Graft survival was superb in both arms, whereas CMV infections were slightly higher in the control arm, attributed to steroid boluses to treat the rejections.19 Basiliximab therapy also shown reduce rejection rates with triple maintenance immunosuppression (cyclosporine, prednisone, and azathioprine or mycophenolate) with related rates of infection and adverse drug events, as compared with placebo.16 Although daclizumab demonstrated similar effects with both 2 and 5-dose regimens, in 2009 2009, it was withdrawn from the market for use in transplantation by Roche, related to a business decision.16,21 TABLE 1 Select pivotal RCTs from 1970 to 2010 in kidney transplantation 0.05. The late 1990s also saw the dramatic rise in rATG use for induction therapy in the United States. This agent was long-approved in Europe, but only received FDA authorization for use in the United States in 1998. Promising data were produced from several randomized controlled tests (RCTs). The most notable was the study by Brennan and colleagues (Table 1), which shown a 4% 1-yr acute rejection rate with rATG induction, as compared with 25% in those receiving hATG. Graft survival was related, but CMV illness rates were two-thirds reduced the rATG arm. All received cyclosporine, azathioprine, and prednisone maintenance therapy.18 The bottom panel of Number 122,23 displays induction therapy use of hATG, rATG, and basiliximab from 1995 to 2004 in kidney transplantation. By the end of this 10-yr period, the majority of kidney recipients were receiving some form of antibody induction; whereas the use of hATG fell out of favor, rATG became the predominant agent of choice, followed by basiliximab and daclizumab (before withdrawal from the market).19,21,22 This tendency continues today, with the vast majority of kidney R406 besylate transplant recipients receiving antibody induction therapy.23 Antibody induction therapy in other solid organ transplant recipients differs substantially, both Rabbit Polyclonal to BLNK (phospho-Tyr84) historically and in current practice. Very few liver recipients receive induction therapy, whereas heart and lung recipients get less than kidneys, but more than livers. Anti-CD25 providers are not generally used in thoracic transplantation, and the agent of choice was, and continues to be, rATG.15,24C26 Open in a separate window FIGURE 1 Maintenance (top panel) and induction (bottom panel) immunosuppression utilization in US Kidney Transplant Recipients 1995 to 2004.22,24C26 AZA, azathioprine; Bas, basiliximab; CyA, cyclosporine; hATG, horse antilymphocyte globulin; hATG, horse antithymocyte globulin; MMF, mycophenolate; rATG, rabbit antilymphocyte globulin; rATG, rabbit antithymocyte globulin;.